PD-L1 expression in nonclear-cell renal cell carcinoma

Annals of Oncology

Volumn 25, Issue 11, 2014, Pages 2178-2184

  Choueiri, T K ^a,b,c   Fay, A P ^a   Gray, K P ^d   Callea, M ^b   Ho, T H ^e   Albiges, L ^a   Bellmunt, J ^a,b,c   Song, J ^b   Carvo, I ^b   Lampron, M ^a   Stanton, M L ^e   Hodi, F S ^a,c   McDermott, D F ^c,f   Atkins, M B ^g   Freeman, G J ^a,c   Hirsch, M S ^b,c   Signoretti, S ^b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MAYO CLINIC   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

Author keywords

Benign kidney tumors; Immunotherapy; Nonclear cell renal cell carcinoma; PD 1 inhibitors; PD L1; Renal cell carcinoma

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADULT; AGED; ANGIOMYOLIPOMA; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CELL MEMBRANE; CHROMOSOME TRANSLOCATION X; CHROMOSOME XP; COLLECTING DUCT CARCINOMA; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; ONCOCYTOMA; OVERALL SURVIVAL; PAPILLARY RENAL CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR CELL MEMBRANE; TUMOR INFILTRATING MONONUCLEAR CELL; TUMOR RECURRENCE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84984919880     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu445     Document Type: Article

References (30)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
2. Choueiri TK. Renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: xiii-xiv.
3. WHO. Kidney Cancer-Pathological Classification. Lyon, France: IARC press 2004.
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
5. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-1657.
6. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw 2009; 7: 659-665.
7. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 2376-2381.
8. Bellmunt J, Choueiri TK, Fougeray R et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-1855.
9. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161: 381-386; discussion 386-387.
10. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renalcell carcinoma. N Engl J Med 2013; 369: 722-731.
11. Sonpavde G, Choueiri TK. Precision medicine for metastatic renal cell carcinoma. Urol Oncol 2013; 32: 5-15.
12. Chowdhury S, Matrana MR, Tsang C et al. Systemic therapy for metastatic nonclear-cell renal cell carcinoma: recent progress and future directions. Hematol Oncol Clin North Am 2011; 25: 853-869.
13. Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J 2013; 19: 316-323.
14. Bellmunt J, Dutcher J. Targeted therapies and the treatment of non-clear cell renal cell carcinoma. Ann Oncol 2013; 24: 1730-1740.
15. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26: 202-209.
16. Green MR, Monti S, Rodig SJ et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-3277.
17. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-17179.
18. Thompson RH, Kuntz SM, Leibovich BC et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006; 66: 3381-3385.
19. Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007; 13: 709s-715s.
20. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
21. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
22. Cho DC, Sosman JA, Sznol M et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). 2013 ASCO Annual Meeting, Chicago, IL, 2013.
23. Choueiri TK, Fishman MN, Escudier BJ et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): biomarker-based results from a randomized clinical trial. J Clin Oncol 2014; 32(5s): (suppl; abstr 5012).
24. Boorjian SA, Sheinin Y, Crispen PL et al. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology 2009; 74: 1359-1364.
25. Webster WS, Lohse CM, Thompson RH et al. Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006; 107: 46-53.
26. Thompson RH, Dong H, Lohse CM et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13: 1757-1761.
27. Malouf GG, Camparo P, Molinie V et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol 2011; 185: 24-29.
28. Malouf GG, Camparo P, Oudard S et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21: 1834-1838.
29. Delahunt B, Cheville JC, Martignoni G et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37: 1490-1504.
30. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127-131.